Electra Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for ELA026, an antibody therapy to treat hemophagocytic lymphohistiocytosis (HLH).
Ramucirumab, which is an antiangiogenic therapy, was evaluated in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ)
The study demonstrated that the Tecentriq combination has more effectively reduced the disease progression in patients compared to those who received Avastin plus chemotherapy. IMpower150 is a multicenter,
The trial, dubbed MONALEESA-7, saw Kisqali, a CDK4/6 inhibitor, combined with an aromatase inhibitor or tamoxifen and goserelin as initial endocrine-based therapy pitted against endocrine therapy and goserelin alone.
Janssen Biotech, along with AbbVie’s Pharmacyclics, has developed Imbruvica, which is a first-in-class Bruton's tyrosine kinase inhibitor. iNNOVATE is a Pharmacyclics-sponsored, randomized, placebo-controlled and double-blind study designed to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
